Denali Therapeutics (DNLI) EBITDA Margin (2018 - 2023)
Denali Therapeutics (DNLI) reported EBITDA Margin of 7779.24% for Q3 2023, up 4813271.0% year-over-year from N/an in Q3 2022, and down 12504.13% quarter-over-quarter from 62.71% in Q2 2023.
Denali Therapeutics (DNLI) EBITDA Margin (2018 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 6 years of EBITDA Margin data on file, last reported at 7779.24% in Q3 2023.
- EBITDA Margin for Q3 2023 came in at 7779.24%, up 4813271.0% year-over-year; the trailing twelve-month figure through Jun 2024 was 33218.0% (down 3318337.0% YoY), and the FY2023 annual result was 41.66%, up 968106.0% from the prior year.
- EBITDA Margin retreated to 7779.24% in Q3 2023 per DNLI's latest filing, from 62.71% in the prior quarter.
- Over five years, EBITDA Margin peaked at 77.22% in Q4 2020 and troughed at 7002800.0% in Q1 2021.
- A 5-year average of 445480.6% and a median of 1009.78% in 2020 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin tumbled 689457308 bps in 2021, then surged 700262921 bps in 2022.
- A 5-year view of EBITDA Margin shows it stood at 1236.26% in 2019, then soared by 106 bps to 77.22% in 2020, then plunged by 899 bps to 617.22% in 2021, then sank by 52 bps to 937.11% in 2022, then tumbled by 730 bps to 7779.24% in 2023.
- Business Quant data shows DNLI's EBITDA Margin at 7779.24% in Q3 2023, 62.71% in Q2 2023, and 299.97% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -7,779.24% |
| Jun 30, 2023 | 62.71% |
| Mar 31, 2023 | -299.97% |
| Dec 31, 2022 | -937.11% |
| Sep 30, 2022 | -55,911.96% |
| Jun 30, 2022 | -117.79% |
| Mar 31, 2022 | -170.79% |
| Dec 31, 2021 | -617.22% |
| Sep 30, 2021 | -1,603.42% |
| Jun 30, 2021 | -405.51% |
| Mar 31, 2021 | -7,002,800.00% |
| Dec 31, 2020 | 77.22% |
| Sep 30, 2020 | -1,175,360.00% |
| Jun 30, 2020 | -1,009.78% |
| Mar 31, 2020 | -108,226.92% |
| Dec 31, 2019 | -1,236.26% |
| Sep 30, 2019 | -48,517.71% |
| Jun 30, 2019 | -58,373.74% |
| Mar 31, 2019 | -903.95% |
| Dec 31, 2018 | 62.33% |